Autopsy report · NCT01329250

Pharmacokinetics and Safety of Moxifloxacin

“slow enrolment of patients and new insights”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 5 years 3 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

University Medical Center Groningen

Sponsor type

University, hospital or other

Conditions

Tuberculosis

Interventions

Moxifloxacin

Participants

9

Sites

1

Countries

Netherlands

Trials that died the same way

• Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism
  “Due to slow inclusion of patients” (71% match in meaning)
• Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure
  “Slow enrolment.” (71% match in meaning)
• IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer
  “it's too slow to enroll suitable patients into this study” (71% match in meaning)
• Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
  “study was stopped after enrolment of about 200 patients for slow recruitment” (70% match in meaning)
• Influence of Body Position on the Defecation Model During Anorectal Manometry.
  “Low rate of enrolment of patients in control group” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.